ZAI LAB LIMITED (ZLAB) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $3.37B; Treasury Stock, Common, ValueUSD $33.52M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $214.00K.
- 2026-03-31: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $3.36B; Treasury Stock, Common, ValueUSD $31.32M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $15.11M.
- 2025-12-31: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $3.34B; Treasury Stock, Common, ValueUSD $29.05M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $29.70M.
- 2025-09-30: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $3.33B; Treasury Stock, Common, ValueUSD $29.05M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $39.65M.
ZAI LAB LIMITED Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Common, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Value USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.00K | $3.37B | $33.52M | $214.00K | $-2.73B | $607.04M | 9.78M | (m) | 3 month · $11.94M | (m) | (m) |
| 2026-03-31 | $7.00K | $3.36B | $31.32M | $15.11M | $-2.68B | $661.98M | 8.60M | (m) | 3 month · $13.52M | (m) | (m) |
| 2025-12-31 | $7.00K | $3.34B | $29.05M | $29.70M | $-2.63B | $715.50M | 7.43M | (m) | 12 month · $65.60M | (m) | (m) |
| 2025-09-30 | $7.00K | $3.33B | $29.05M | $39.65M | $-2.58B | $759.95M | 7.43M | (m) | 3 month · $16.92M | (m) | (m) |
| 2025-06-30 | $7.00K | $3.31B | $20.86M | $46.35M | $-2.54B | $791.74M | 4.92M | (m) | 3 month · $16.97M | (m) | (m) |
| 2025-03-31 | $7.00K | $3.28B | $20.84M | $49.30M | $-2.50B | $810.75M | 4.91M | 3 month · $28.00K | 3 month · $15.80M | (m) | (m) |
| 2024-12-31 | $7.00K | $3.26B | $20.84M | $50.52M | $-2.45B | $840.90M | 4.91M | 12 month · $2.28M | 12 month · $70.65M | (m) | (m) |
| 2024-09-30 | $6.00K | $3.03B | $20.84M | $28.27M | $-2.37B | $667.67M | 4.91M | (m) | 3 month · $16.80M | (m) | (m) |
| 2024-06-30 | $6.00K | $3.01B | $20.84M | $42.77M | $-2.33B | $704.18M | 4.91M | (m) | 3 month · $18.64M | (m) | (m) |
| 2024-03-31 | $6.00K | $2.99B | $20.84M | $39.17M | $-2.25B | $762.17M | 4.91M | (m) | 3 month · $17.98M | (m) | (m) |
| 2023-12-31 | $6.00K | $2.98B | $20.84M | $37.63M | $-2.20B | $796.12M | 4.91M | (m) | 12 month · $79.63M | (m) | (m) |
| 2023-09-30 | $6.00K | $2.95B | $20.79M | $47.95M | $-2.10B | $880.98M | 4.89M | (m) | 3 month · $21.99M | (m) | (m) |
| 2023-06-30 | $6.00K | $2.93B | $20.53M | $52.18M | $-2.03B | $932.31M | 4.79M | (m) | 3 month · $20.51M | (m) | (m) |
| 2023-03-31 | $6.00K | $2.91B | $16.99M | $17.27M | $-1.91B | $1.00B | 3.51M | (m) | 3 month · $16.66M | (m) | (m) |
| 2022-12-31 | $6.00K | $2.89B | $11.86M | $25.68M | $-1.86B | $1.05B | 2.24M | (m) | 12 month · $61.30M | (m) | (m) |
| 2022-09-30 | $6.00K | $2.88B | $11.46M | $39.55M | $-1.80B | $1.11B | 2.10M | (m) | 3 month · $19.11M | (m) | (m) |
| 2022-06-30 | $6.00K | $2.86B | $11.13M | $4.49M | $-1.64B | $1.21B | 2.03M | (m) | 3 month · $14.22M | (m) | (m) |
| 2022-03-31 | $6.00K | $2.84B | (m) | $-25.84M | $-1.50B | $1.31B | (m) | (m) | 3 month · $12.41M | $4.35M | 398.08K |
| 2021-12-31 | $6.00K | $2.83B | $4.28M | $-23.64M | $-1.42B | $1.38B | 382.93K | 12 month · $839.00K | 12 month · $40.71M | $4.28M | 382.93K |
| 2021-09-30 | $6.00K | $2.81B | (m) | $-15.12M | $-1.21B | $1.59B | (m) | (m) | 3 month · $10.56M | $3.53M | 27.72K |
| 2021-06-30 | $6.00K | $2.80B | (m) | $-16.86M | $-1.11B | $1.67B | (m) | 3 month · $879.00K | 3 month · $10.23M | $924.00K | 6.09K |
| 2021-03-31 | $5.00K | $1.97B | (m) | $-11.62M | $-946.51M | $1.01B | (m) | (m) | 3 month · $7.32M | (m) | (m) |
| 2020-12-31 | $5.00K | $1.90B | (m) | $-14.52M | $-713.60M | $1.17B | (m) | 12 month · $746.00K | 12 month · $24.83M | $0.00 | 0.00 |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $1.14B | (m) | (m) | 3 month · $6.98M | (m) | (m) |
| 2020-06-30 | $4.00K | $1.03B | (m) | $6.99M | $-573.32M | $465.47M | (m) | 3 month · $13.00K 6 month · $740.00K | 3 month · $6.96M 6 month · $13.43M | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $537.59M | (m) | 3 month · $740.00K | 3 month · $6.46M | (m) | (m) |
| 2019-12-31 | $4.00K | $734.73M | (m) | $4.62M | $-444.70M | $294.66M | (m) | 12 month · $854.00K | 12 month · $20.29M | (m) | (m) |
| 2019-09-30 | $4.07K | $728.41M | (m) | $6.97M | $-398.27M | $337.11M | (m) | (m) | 9 month · $14.55M | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $393.33M | (m) | 6 month · $839.00K | 6 month · $9.29M | (m) | (m) |
| 2018-12-31 | $3.00K | $498.04M | (m) | $2.66M | $-249.63M | $251.08M | (m) | 12 month · $652.00K | 12 month · $12.23M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $309.06M | (m) | (m) | 9 month · $8.00M | (m) | (m) |
| 2017-12-31 | $3.00K | $345.27M | (m) | $449.91K | $-110.55M | $235.17M | (m) | 12 month · $2.77M | 12 month · $9.93M | (m) | (m) |
| 2016-12-31 | $579.00 | $9.31M | (m) | $-698.53K | $-60.17M | $-51.55M | (m) | (m) | 12 month · $4.93M | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | $-18.37M | (m) | (m) | 12 month · $2.70M | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | $-2.95M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |